In 2023, the Federal Court of Canada released more patent motion
decisions than motion decisions in all other IP rights
combined:

Within the patent proceedings, there was a split between
decisions involving pharma and biologic patents (58%) and those
involving other technologies (42%). This illustrates that patent
litigation in Canada continues to be dominated by pharma/generic
and biologic/biosimilar proceedings under the PMNOC
Regulations:

Classification
We have attempted to classify the motion types into several
broad categories that reflect the stages of litigation from
commencement through to trial: (i) pleadings (for example,
amendments to pleadings and striking out pleadings), document and
oral discovery and expert evidence (for example, production
motions, motions to compel, seeking leave for reply expert
evidence, and striking expert reports), procedural (appeals of
associate judge decisions, adjournments, deadlines, and security
for costs),